Lung Disease

65

Pipeline Programs↗

7

Active Trials↗

26

Companies Involved↗

Lung Disease is a moderately active landscape with 65 programs across 26 companies. The most active players are Mylan Pharmaceuticals Inc, Orphanetics Pharma Entwicklungs GmbH, Arrowhead Pharmaceuticals. 23 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

6/100

Mech. Concentration

9/100

Completion Rate

77/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Mylan Pharmaceuticals Inc

1 program

Orphanetics Pharma Entwicklungs GmbH

1 program

Arrowhead Pharmaceuticals

2 programs

Takeda

1 program

Novo Nordisk

1 program

AstraZeneca

4 programs

Pipeline

Programs by Phase

Preclinical14

Alfentanil

Alnylam Pharmaceuticals

Nintedanib

Boehringer Ingelheim

Propofol

Fresenius Kabi Oncology Ltd.

Bupivacaine

Innocoll

Abatacept

Bristol-Myers Squibb

Phase 16

Albuterol Sulfate

Mylan Pharmaceuticals Inc

Simvastatin

Organon and Co

Hyperpolarized Xe129

University of Kansas Medical Center

Xenon Gas

University Hospitals Bristol and Weston NHS Foundation Trust

Tetrahydrobiopterin

Orphanetics Pharma Entwicklungs GmbH

Phase 211

Prednisone

Roxane Laboratories

Tocilizumab

Roche

Ixazomib

Takeda

Dapsone

Almirall, S.A.

Amikacin

Insmed Incorporated

Phase 311

Cyclophosphamide

Baxter Healthcare Corporation

Rituximab

Roche

Bedaquiline

Wim Janssens

Rifampicin

Boehringer Ingelheim

Lumacaftor

Vertex Pharmaceuticals

Approved23

Triamcinolone

Bassett Healthcare

Ciprofloxacin

Bayer

Furosemide

Validus Pharmaceuticals

Nitric Oxide

Mallinckrodt

Ketamine

Aultman Health Foundation

Analysis

Modality Breakdown

93%

Small molecule

68 of 73 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 73 classified programs, each share of the total. Modality classified for 100% of 75 pipeline programs.

Analysis

Trial Status

44

clinical trials

Completed24 · 55%

Recruiting5 · 11%

Terminated5 · 11%

Unknown status5 · 11%

Withdrawn2 · 5%

No longer available1 · 2%

Other2 · 5%

Clinical Trials

Trial Activity

44 trials

A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease

Recruiting·TThe Aurum Institute NPC·N/A·NCT06909799·242 enrolled

Regional Monitoring of CF Lung Disease

Recruiting·—·Phase 1·NCT06339593·60 enrolled

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

Recruiting·UUniversity of Florida·N/A·NCT01851642·220 enrolled

Feasibility of Semaglutide in Advanced Lung Disease

Recruiting·UUniversity of Pennsylvania·Phase 1/2·NCT05746039·8 enrolled

Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)

Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT00001465·2,000 enrolled

Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

Not yet recruiting·—·Phase 2·NCT07301320·84 enrolled

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Enrolling by invitation· United Therapeutics logo

United Therapeutics·Phase 3·NCT04905693·1,850 enrolled

The Effects of Broccoli Sprout Extract on Obstructive Lung Disease

Completed·JJohns Hopkins University·N/A·NCT00994604·51 enrolled

Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)

Completed·VVA Loma Linda Health Care System·Phase 1·NCT00655993·30 enrolled

Effects of Dexmedetomidine on Respiratory Mechanics and Oxygenation During One Lung Ventilation With Chronic Obstructive Lung Disease

Completed·YYonsei University·N/A·NCT02185430·63 enrolled

Image and Model Based Analysis of Lung Disease

Completed·—·Phase 1·NCT03764163·341 enrolled

Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx)

Completed·RRoyal Brompton & Harefield NHS Foundation Trust·Phase 4·NCT02286063·70 enrolled

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

Completed·—·Phase 4·NCT00139152·65 enrolled

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 3·NCT02390219·46 enrolled

Lung Sounds as Indicators of Severity and Recovery of Lung Disease

Completed·—·N/A·NCT02053870·98 enrolled

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)